Biota Pharmaceuticals Inc. (NASDAQ:AVIR) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus target price of $4.50 for the company and are forecasting that the company will post ($0.24) EPS for the current quarter, according to Zacks. Zacks has also given Biota Pharmaceuticals an industry rank of 93 out of 265 based on the ratings given to its competitors.
A number of brokerages recently commented on AVIR. Ladenburg Thalmann began coverage on Biota Pharmaceuticals in a research report on Wednesday, September 21st. They set a “buy” rating for the company. HC Wainwright reaffirmed a “buy” rating on shares of Biota Pharmaceuticals in a research report on Tuesday, September 20th.
A number of institutional investors have recently made changes to their positions in the stock. BVF Inc. IL purchased a new position in shares of Biota Pharmaceuticals during the second quarter valued at $292,000. Eagle Global Advisors LLC purchased a new position in shares of Biota Pharmaceuticals during the second quarter valued at $381,000. Bridgeway Capital Management Inc. purchased a new position in shares of Biota Pharmaceuticals during the second quarter valued at $300,000. Senzar Asset Management LLC purchased a new position in shares of Biota Pharmaceuticals during the second quarter valued at $2,848,000. Finally, FMR LLC purchased a new position in shares of Biota Pharmaceuticals during the second quarter valued at $420,000. 34.53% of the stock is owned by institutional investors and hedge funds.
Biota Pharmaceuticals (NASDAQ:AVIR) opened at 1.75 on Wednesday. The firm has a 50-day moving average price of $1.55 and a 200 day moving average price of $1.49. The firm’s market capitalization is $67.62 million. Biota Pharmaceuticals has a one year low of $1.23 and a one year high of $2.28.
Biota Pharmaceuticals (NASDAQ:AVIR) last issued its quarterly earnings results on Wednesday, September 14th. The company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of $0.25 by $0.43. Biota Pharmaceuticals had a negative net margin of 272.04% and a negative return on equity of 46.02%. Analysts anticipate that Biota Pharmaceuticals will post ($0.93) EPS for the current fiscal year.
Biota Pharmaceuticals Company Profile
Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals Inc, is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biota Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biota Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.